Adocia SA (ADOCF) Starts Presentation at 29th Annual ROTH Conference
Adocia SA (OTC: ADCOF) a clinical-stage biotechnology company, develops medicines using therapeutic molecules. Its product pipeline includes BioChaperone PDGF, which is in phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone Combo insulin that is in phase I/II clinical trials, as well as in pre-clinical stage for the treatment of diabetes; BioChaperone Lispro U100 that is in phase Ib clinical study for type 1 diabetes patients using an insulin pump; BioChaperone human insulin, which is in phase II clinical trials; and DriveIn, which is in preclinical stage for the treatment of oncology, as well as monoclonal antibodies…







